These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33372855)

  • 21. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.
    Salim DK; Mutlu H; Eryilmaz MK; Musri FY; Tural D; Gunduz S; Coskun HS
    Asian Pac J Cancer Prev; 2014; 15(21):9379-83. PubMed ID: 25422228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer.
    Jukkola-Vuorinen A; Rahko E; Vuopala KS; Desmond R; Lehenkari PP; Harris KW; Selander KS
    J Innate Immun; 2009; 1(1):59-68. PubMed ID: 20375566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a proliferation essential gene signature and actin-like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple-positive breast cancer.
    Li X; Luo S; Fu W; Huang M; Huang X; Kang S; Zhang J; Wang Q; Song C
    Cancer; 2024 Apr; 130(S8):1435-1448. PubMed ID: 38358781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
    Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
    Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
    Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SPLUNC1 reduces the inflammatory response of nasopharyngeal carcinoma cells infected with the EB virus by inhibiting the TLR9/NF-κB pathway.
    Ou C; Sun Z; Zhang H; Xiong W; Ma J; Zhou M; Lu J; Zeng Z; Bo X; Chen P; Li G; Li X; Li X
    Oncol Rep; 2015 Jun; 33(6):2779-88. PubMed ID: 25891128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
    Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
    Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
    Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients.
    König L; Kasimir-Bauer S; Hoffmann O; Bittner AK; Wagner B; Manvailer LF; Schramm S; Bankfalvi A; Giebel B; Kimmig R; Horn PA; Rebmann V
    Hum Immunol; 2016 Sep; 77(9):791-9. PubMed ID: 26796737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer.
    Singh M; Capocelli KE; Marks JL; Schleicher RB; Finlayson CA; Seligman PA
    Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):147-56. PubMed ID: 15894927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
    Cerbelli B; Pernazza A; Botticelli A; Fortunato L; Monti M; Sciattella P; Campagna D; Mazzuca F; Mauri M; Naso G; Marchetti P; d'Amati G; Costarelli L
    Biomed Res Int; 2017; 2017():1750925. PubMed ID: 29387716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer.
    Roy-Luzarraga M; Abdel-Fatah T; Reynolds LE; Clear A; Taylor JG; Gribben JG; Chan S; Jones L; Hodivala-Dilke K
    JAMA Netw Open; 2020 Oct; 3(10):e2019304. PubMed ID: 33107920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
    Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
    Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
    Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
    Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival.
    Liu LT; Chen QY; Tang LQ; Zhang L; Guo SS; Xie CM; Liu XW; Guo L; Mo HY; Chen MY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Radiology; 2017 Jan; 282(1):171-181. PubMed ID: 27479804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor Location and Survival Outcomes in Adult Patients with Supratentorial Glioblastoma by Levels of Toll-Like Receptor 9 Expression.
    Mu L; Wang Y; Wang Y; Zhang H; Shang D; Tan F; Li Y; Chen X
    World Neurosurg; 2017 Jan; 97():279-283. PubMed ID: 27744078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
    LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
    Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
    Sicchieri RD; da Silveira WA; Mandarano LR; de Oliveira TM; Carrara HH; Muglia VF; de Andrade JM; Tiezzi DG
    Tumour Biol; 2015 Dec; 36(12):9233-43. PubMed ID: 26091795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.